Viking Therapeutics

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual agonist of the GLP-1 and GIP receptors being developed in subcutaneous and oral formulations for obesity and related conditions, with the Phase 3 VANQUISH 1 and 2 subcutaneous trials fully enrolled and an oral Phase 3 programme initiating. In September 2026 the company reported positive topline results from a maintenance-dosing study of subcutaneous VK2735, showing 17.7% mean weight loss after a 21-week induction phase with efficacy maintained under less frequent dosing regimens. The pipeline also includes VK2809, an oral thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis, and VK0214 for X-linked adrenoleukodystrophy.